Skip to main content
Erschienen in: Journal of Neuro-Oncology 1/2019

25.06.2019 | Letter to the Editor

A review of eligibility for patients with central nervous system (CNS) metastases from non-small cell lung cancer (NSCLC) in immunotherapy clinical trials

verfasst von: Saba S. Shaikh, Priya U. Kumthekar, Nisha A. Mohindra

Erschienen in: Journal of Neuro-Oncology | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

To the Editor, …
Literatur
1.
Zurück zum Zitat Zhou J, Gong Z, Jia Q, Wu Y, Yang ZZ, Zhu B (2018) Programmed death ligand 1 expression and CD8(+) tumor-infiltrating lymphocyte density differences between paired primary and brain metastatic lesions in non-small cell lung cancer. Biochem Biophy Res Commun 498:751–757CrossRef Zhou J, Gong Z, Jia Q, Wu Y, Yang ZZ, Zhu B (2018) Programmed death ligand 1 expression and CD8(+) tumor-infiltrating lymphocyte density differences between paired primary and brain metastatic lesions in non-small cell lung cancer. Biochem Biophy Res Commun 498:751–757CrossRef
2.
Zurück zum Zitat Reck M, Rodriguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823–1833CrossRef Reck M, Rodriguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823–1833CrossRef
3.
Zurück zum Zitat Rittmeyer A, Barlesi F, Waterkamp D et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389:255–265CrossRefPubMed Rittmeyer A, Barlesi F, Waterkamp D et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389:255–265CrossRefPubMed
4.
Zurück zum Zitat Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627–1639CrossRefPubMedPubMedCentral Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627–1639CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Gauvain C, Vauleon E, Chouaid C et al (2018) Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases. Lung Cancer 116:62–66CrossRefPubMed Gauvain C, Vauleon E, Chouaid C et al (2018) Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases. Lung Cancer 116:62–66CrossRefPubMed
6.
Zurück zum Zitat Sarah B, Goldberg SN, Mahajan A, Herbst RS, Chiang AC, Lilenbaum R, Jilaveanu L, Rowen E, Gerrish H, Komlo A, Wei W, Chiang V, Kluger HM (2018) Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab. 2018 ASCO Annual Meeting Abstract. Sarah B, Goldberg SN, Mahajan A, Herbst RS, Chiang AC, Lilenbaum R, Jilaveanu L, Rowen E, Gerrish H, Komlo A, Wei W, Chiang V, Kluger HM (2018) Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab. 2018 ASCO Annual Meeting Abstract.
7.
Zurück zum Zitat Pinato DJ, Shiner RJ, White SD et al (2016) Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: Implications for immunotherapy. Oncoimmunology 5:e1213934CrossRefPubMedPubMedCentral Pinato DJ, Shiner RJ, White SD et al (2016) Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: Implications for immunotherapy. Oncoimmunology 5:e1213934CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Brastianos PK, Prakandan S, Alvarez-Breckenridge C, Lee WQ, Tolaney SM, Nayak L, Lin NU, Navia A, Bihun I, Chukwueke UN, Oh KS, White M, Gerstner ER, Lawrence DP, Cohen JV, Giobbie-Hurder A, Cahill DP, Shalek A, Carter SL, Sullivan RJ (2018) Phase II study of pembrolizumab in leptomeningeal carcinomatosis. 2018 ASCO Annual Meeting Abstract Brastianos PK, Prakandan S, Alvarez-Breckenridge C, Lee WQ, Tolaney SM, Nayak L, Lin NU, Navia A, Bihun I, Chukwueke UN, Oh KS, White M, Gerstner ER, Lawrence DP, Cohen JV, Giobbie-Hurder A, Cahill DP, Shalek A, Carter SL, Sullivan RJ (2018) Phase II study of pembrolizumab in leptomeningeal carcinomatosis. 2018 ASCO Annual Meeting Abstract
9.
Zurück zum Zitat Pfannenstiel LW, McNeilly C, Xiang C et al (2019) Combination PD-1 blockade and irradiation of brain metastasis induces an effective abscopal effect in melanoma. Oncoimmunology 8:e1507669CrossRefPubMed Pfannenstiel LW, McNeilly C, Xiang C et al (2019) Combination PD-1 blockade and irradiation of brain metastasis induces an effective abscopal effect in melanoma. Oncoimmunology 8:e1507669CrossRefPubMed
10.
Zurück zum Zitat Camidge DR, Lee EQ, Lin NU et al (2018) Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the response assessment in Neuro-Oncology Brain Metastases working group. The Lancet Oncol 19:e20–e32CrossRefPubMed Camidge DR, Lee EQ, Lin NU et al (2018) Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the response assessment in Neuro-Oncology Brain Metastases working group. The Lancet Oncol 19:e20–e32CrossRefPubMed
11.
Zurück zum Zitat Lin NU, Prowell T, Tan AR et al (2017) Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology–Friends of Cancer Research Brain Metastases Working Group. J Clin Oncol 35:3760–3773CrossRefPubMed Lin NU, Prowell T, Tan AR et al (2017) Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology–Friends of Cancer Research Brain Metastases Working Group. J Clin Oncol 35:3760–3773CrossRefPubMed
Metadaten
Titel
A review of eligibility for patients with central nervous system (CNS) metastases from non-small cell lung cancer (NSCLC) in immunotherapy clinical trials
verfasst von
Saba S. Shaikh
Priya U. Kumthekar
Nisha A. Mohindra
Publikationsdatum
25.06.2019
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 1/2019
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-019-03219-7

Weitere Artikel der Ausgabe 1/2019

Journal of Neuro-Oncology 1/2019 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.